Head of Hong Kong’s new drug regulator pledges to build trust, push innovation

The head of Hong Kong’s new drug regulatory body has pledged to build a fully capable and globally trusted agency that will become a catalyst for medical innovation rather than merely acting as a “miniature version” of existing overseas models. Dr Li Zili, controller of the Hong Kong Centre for Medical Products Regu…

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.